On March 21, 2022 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that it will present a poster on the company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13, 2022 onsite in New Orleans, LA and online (Press release, Kineta, MAR 21, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-present-poster-on-anti-cd27-agonist-antibody-program-at-the-aacr-annual-meeting-2022 [SID1234610465]). Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of blood cancers and solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Abstract Number: 5588
Presenter: Thierry Guillaudeux, PhD
Session Type: In-Person and e-Poster Presentation
Session Title: Therapeutic Antibodies 3
Session Time: April 13, 2022 9:00AM – 12:30PM Central Time
Location: Poster Section 39
CD27 is a clinically validated drug target. It is a member of the TNF receptor superfamily and plays a critical role in T-cell activation by providing a co-stimulatory signal together with its ligand CD70. CD27 is highly expressed on naïve T cells and also provides a co-stimulatory signal for NK cell activation. Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nM binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation, NK activation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in mid-2022.